On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Department of Chemistry and Beckman Institute for Advanced Science and Technology, University of Illinois Urbana−Champaign, Urbana, Illinois 61801, United States Neuroscience Program, University of ...

I'm diving deep into the intersection of infrastructure and machine learning. I'm fascinated by exploring scalable architectures, MLOps, and the latest advancements in AI-driven systems ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.48, moving -1.52% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.22% for ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

Despite near-significant Phase 2 data, Recursion's lead drug REC-994 for CCM remains unconvincing as a validation of their AI platform, being a repurposed compound. Pipeline expansion in oncology ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.